Latest Breaking News On - International prognostic index - Page 1 : vimarsana.com

Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2

Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.

Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCL

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

How Does Metabolic Tumor Volume Affect Responses to Axi-Cel in LBCL?

The authors say a standard method of assessing metabolic tumor volume would be needed for its use to become widespread.

Follicular Lymphoma - Causes, Symptoms, Diagnosis, Treatment and Prevention

Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL

Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.

Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

Recent Approvals Across Hematologic Malignancies Usher in a New Era

Mikkael A. Sekeres, MD, MS, highlights recent approvals and emerging therapeutics in hematologic malignancies discussed by his colleagues.

Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.

Clinical Challenges: Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

Questions remain on how best to diagnose and treat CNS involvement in high-risk groups

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients With Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.